Date:4/2/2012

ntial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.   These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ending December 31, 2011 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145ULURU Inc.SUMMARY OF RESULTSSTATEMENTS OF OPERATIONS DATA(Unaudited)(Audited)Three Months Ended December 31, Years Ended December 31,2011201020112010REVENUESLicense fees

$
4,494$   949,271$
22,843$  1,099,554Royalty income

17,12725,99168,656158,464Product sales

233,90553,614393,037299,339Total Revenues

255,5261,028,876484,5361,557,357COSTS AND EXPENSESCost of goods sold

167,60810,211203,154153,470Research and development

197,504309,100946,5531,258,060Selling, general and administrative

497,761714,7582,276,8063,119,881Amortization of intangible assets

156,500206,454769,132905,706Depreciation

75,35977,020303,024256,073Total Costs and Expenses

1,094,7321,317,5434,498,6695,693,190OPERATING (LOSS)(839,206)(288,667)(4,014,133)(4,135,833)Other Income (Expense)Interest and miscellaneous income

1,8
'/>"/>

SOURCE ULURU Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing